Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine

01-04-2016 | Cerebrovascular Disease and Stroke (N Rost, Section Editor)

Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation

Authors: Rochelle Sweis, DO, José Biller, MD, FACP, FAAN, FANA, FAHA

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 4/2016

Login to get access

Opinion statement

Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.
Literature
1.•
Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131:2176–84. This study demonstrates the need for screening for AF which can go undiagnosed resulting in more strokes among the elderly.CrossRefPubMed
2.
Cope S, Clemens A, Hammes F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. Value Health. 2015;18(2):234–49.CrossRefPubMed
3.
Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med (Hagerstown). 2014;15(12):873–9.CrossRef
4.•
Holmes DR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2015;65(24):2614–23. Controversy of using left atrial appendage closure for secondary stroke prevention as opposed to warfarin is discussed. In this trial, patients had less cardiac and hemorrhagic strokes but an increase in ischemic strokes.CrossRefPubMed
5.
Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015;386(9990):303–10.CrossRefPubMed
6.•
Granger CB, Alexander JH, McMurray JJ, Lopez RD, Hylek EM, Hanna M, et al. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. This article discusses the ARISTOTLE trial, comparing apixaban to warfarin for secondary stroke prevention of NVAV.CrossRefPubMed
7.
Lu Y, Branstad R, Karim RM, Asinger RW. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation. J Clin Pharm Ther. 2014;39(6):628–36.CrossRefPubMed
8.•
Hinojar R, Jimenez-Natcher JJ, Fernandez-Golfin C, Zamorano JL. New oral anticoagulants: a practical guide for physicians. Eur Heart J. 2015;1:134–45. A beneficial guide on the NOACs.
9.•
Connolly SJ, Ezekowtiz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. The RE-LY trial is the first trial comparing the NOAC, dabigatran, to warfarin for secondary stroke prevention of NVAF.CrossRefPubMed
10.
Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation—sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75(4):800–5.CrossRefPubMed
11.
Rogan L. Guidance for prescribing of dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) in patients with non-valvular AF (2015). NHS Strategic Clinic Network, Version 8.
12.•
Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study. Circulation. 2013;128(3):237–43. The RELY-ABLE study followed patients on dabigatran from the RE-LY study for two additional years and confirmed results of RELY but also showed no significant differences in stroke or mortality between the two doses except for a higher rate of major bleeding in the increased dose of dabigatran.CrossRefPubMed
13.•
Tsadok MA, Jacketicius CA, Rahme E, et al. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (published online). 2015;8: 00–00. The authors point out the paucity of data associating sex differences with stroke, therefore affecting optimal dosing of anticoagulation for women, specifically dabigatran.
14.
Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol. 2013;20(5):430–6.CrossRefPubMed
15.•
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–55. This trial summarizes the results of the ROCKET-AF trial, comparing rivaroxaban versus warfarin for secondary stroke prevention of NVAF.CrossRefPubMed
16.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMed
17.
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224–32.CrossRefPubMed
18.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.CrossRefPubMed
19.
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–53.CrossRefPubMed
20.
del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med. 2011;365(10):952–3.CrossRefPubMed
21.
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–4.CrossRefPubMed
22.
Verheugt FW. Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd? Eur Heart J. 2013;34(22):1618–20.CrossRefPubMed
23.
Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc. 2014;89(7):896–907.CrossRefPubMed
24.
25.
Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478–92.CrossRefPubMedPubMedCentral
26.••
Gladstone DJ, Geerts WH, Douketis J, Ivers N, Healey JS, Leblanc K. How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med. 2015;163(5):382–5. An article publishing a useful practice tool to guide physicians in monitoring patients taking NOACs.CrossRefPubMed
27.•
Wood SU. Assessing kidney function in oral anticoagulant prescribing: an aid for safer drug and dose choices. Br J Cardiol. 2013;20:61–4. The author discusses the need for ongoing monitoring of renal function in patients taking NOACs in order to avoid adverse effects, specifically bleeding.
28.••
Pollack CV, Reilly PA, Eikelborn J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20. A recent landmark study discussing the antidote for dabigatran.CrossRefPubMed
29.
Ansell JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolyisis. 2015.
30.
Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013;128, A17765.
31.•
Volk T, Kubulus C. New oral anticoagulants and neuraxial regional anesthesia. Curr Opin Anesthesiol. 2015;28:605–9. Safety guidelines for NOACs and neuraxial puncture and anesthesia are discussed.CrossRef
32.
Horlocker TT. Regional anesthesia in the patient receiving antithrombotic and antiplatelet therapy. Br J Anesth. 2011;107(S1):96–106.CrossRef
33.•
Douketis J. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res. 2003;108:3–13. Guidelines for perioperative management of NOACs is provided.CrossRef
34.
Dincq A-S, Lessire S, Douxfils J et al. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Hindawi: Biomed Res Int. 2014;385014.
35.
Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants. Arch Intern Med. 2003;163:901–8.CrossRefPubMed
36.••
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76. Recommendations for the treatment of AF as provided by the AHA/ACC/HRS.CrossRefPubMed
37.
Huang D, Anguo L, Yue WS, Yin L, Tse HF, Siu CW. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2-VASc score of 1. Pacing Clin Electrophysiol. 2014;37(11):1442–7.CrossRefPubMed
38.•
Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65(14):1385–94. Which patients are most at risk for stroke based on CHA2DS2-VASc score and who should be anticoagulated are discussed in this article.CrossRefPubMed
39.
Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9.CrossRefPubMed
40.••
Hankey GJ. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke. 2014;9:627–32. The role of thrombolysis in acute ischemic stroke for patients taking NOACs is an important point discussed in this article.CrossRefPubMedPubMedCentral
41.••
Morgenstren LB, Hemphill JC, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29. Guidelines provided by the AHA/ASA for treatment of ICH.CrossRef
42.
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–420.CrossRef
43.
Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.CrossRefPubMed
44.
Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453–60.CrossRefPubMed
45.
Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381–91.CrossRefPubMed
46.••
Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824–36. A thorough article discussing how to manage coagulopathy related ICH in terms of blood pressure goals and modes of reversal.CrossRefPubMed
47.••
Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med. 2010;77(11):791–9. This article provides a guide for practitioners regarding when in which specific patients to resume anticoagulation after suffering an ICH.CrossRefPubMedPubMedCentral
48.
Rabinstein AA, Gupta A. Restarting anticoagulation after intracranial hemorrhage: a risky decision with no recipe. Neurology. 2014;82(12):1016–7.CrossRefPubMed
49.
Rosand J, Hylek EM, O’Donnell HC, et al. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathological study. Neurology. 2000;55:947–51.CrossRefPubMed
50.
Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87 Suppl 1:S141–5.CrossRefPubMed
51.
Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–49.CrossRefPubMed
52.
Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost. 2012;107(6):1172–9.CrossRefPubMed
53.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefPubMed
Metadata
Title
Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation
Authors
Rochelle Sweis, DO
José Biller, MD, FACP, FAAN, FANA, FAHA
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 4/2016
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-016-0446-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits